NASDAQ:GOVX

GeoVax Labs (GOVX) Stock Forecast, Price & News

$0.57

+0.05 (+9.69%)

(As of 10/2/2023 ET)

Compare

Today's Range: $0.52
▼
$0.60
50-Day Range: $0.51
▼
$0.62
52-Week Range: $0.51
▼
$1.39

Volume: 1.07 million shs
Average Volume: 838,122 shs
Market Capitalization: $14.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

GeoVax Labs MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 783.4% Upside
$5.00 Price Target
Short Interest: Healthy
2.56% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.83
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$30,219 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.64) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

154th out of 975 stocks

Pharmaceutical Preparations Industry

51st out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
GeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, GeoVax Labs has a forecasted upside of 783.4% from its current price of $0.57.
Amount of Analyst Coverage
GeoVax Labs has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.56% of the outstanding shares of GeoVax Labs have been sold short.
Short Interest Ratio / Days to Cover
GeoVax Labs has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GeoVax Labs has recently decreased by 14.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
GeoVax Labs does not currently pay a dividend.
Dividend Growth
GeoVax Labs does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GOVX.

3.2

News and Social Media Coverage

News Sentiment
GeoVax Labs has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for GeoVax Labs this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
1 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,219.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of GeoVax Labs is held by insiders.
Percentage Held by Institutions
Only 6.09% of the stock of GeoVax Labs is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for GeoVax Labs are expected to grow in the coming year, from ($0.64) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GeoVax Labs is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GeoVax Labs is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GeoVax Labs has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GeoVax Labs (NASDAQ:GOVX) Stock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Price History

30 days | 90 days | 365 days | Advanced Chart

GOVX Stock News Headlines

September 27, 2023 | finance.yahoo.com

GeoVax to Participate in Upcoming October Investor and Industry Events

September 26, 2023 | markets.businessinsider.com

GeoVax Labs Secures License Agreement With ProBioGen

October 2, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 19, 2023 | finance.yahoo.com

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

September 12, 2023 | finance.yahoo.com

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023 | finance.yahoo.com

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

August 31, 2023 | msn.com

Geovax Labs (GOVX) Price Target Increased by 11.11% to 6.12

August 31, 2023 | finance.yahoo.com

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

October 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 28, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

August 11, 2023 | finance.yahoo.com

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript

July 26, 2023 | finance.yahoo.com

GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023

July 24, 2023 | markets.businessinsider.com

GeoVax Labs (GOVX) Gets a Buy from Noble Financial

July 24, 2023 | finance.yahoo.com

GeoVax Announces Issuance of Ebola Vaccine Patent

July 20, 2023 | finanznachrichten.de

GeoVax, Inc.: GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

July 20, 2023 | finance.yahoo.com

GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

June 28, 2023 | finance.yahoo.com

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

June 27, 2023 | finance.yahoo.com

GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights

May 31, 2023 | finance.yahoo.com

GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

May 25, 2023 | finance.yahoo.com

GeoVax to Participate in Upcoming Industry Meetings

May 24, 2023 | msn.com

GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results

May 15, 2023 | finance.yahoo.com

GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings

May 9, 2023 | marketwatch.com

GeoVax Labs to Participate in A.G.P.'s Virtual Healthcare Conference

May 9, 2023 | msn.com

Noble Capital Markets Initiates Coverage of Geovax Labs (GOVX) with Outperform Recommendation

May 9, 2023 | msn.com

HC Wainwright & Co. Reiterates Geovax Labs (GOVX) Buy Recommendation

May 4, 2023 | msn.com

Geovax Labs: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

See More Headlines

Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

GOVX Company Calendar

Last Earnings: 8/09/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GOVX
CUSIP: N/A
CIK: 832489
Web: www.geovax.com
Phone: (678) 384-7220
Fax: 678-384-7281
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +802.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,020,000.00
Net Margins: N/A
Pretax Margin: -1,931,699.75%
Return on Equity: -79.25%
Return on Assets: -65.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.85
Quick Ratio: 4.85

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 183.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.01 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 26,440,000
Free Float: 25,386,000
Market Cap: $14.65 million
Optionable: Not Optionable
Beta: 2.87

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. David Alan Dodd (Age 73)
Chairman, Pres & CEO
Comp: $469.01k

Mr. Mark W. Reynolds CPA (Age 61)
CPA, CFO & Corp. Sec.
Comp: $348.2k

Dr. Mark J. Newman Ph.D. (Age 68)
Chief Scientific Officer
Comp: $364.17k

Dr. Harriet Latham Robinson Ph.D. (Age 85)
Founder & Member of Scientific Advisory Board

Dr. Kelly T. McKee Jr. (Age 73)
M.D., M.P.H., Chief Medical Officer

Jeffrey Welch
Head of Process Devel. & Manufacturing Operations

Dr. John W. Sharkey Ph.D. (Age 67)
VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GOVX Stock - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings or view top-rated stocks.
What is GeoVax Labs' stock price forecast for 2023?: 2 brokerages have issued 12 month price targets for GeoVax Labs' shares. Their GOVX share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 802.4% from the stock's current price.
View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts.
How have GOVX shares performed in 2023?: GeoVax Labs' stock was trading at $0.6302 at the beginning of the year. Since then, GOVX shares have decreased by 12.1% and is now trading at $0.5541.
View the best growth stocks for 2023 here.
Are investors shorting GeoVax Labs?: GeoVax Labs saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 676,300 shares, a decline of 14.9% from the August 31st total of 794,700 shares. Based on an average daily trading volume, of 345,200 shares, the short-interest ratio is presently 2.0 days.
View GeoVax Labs' Short Interest.
When is GeoVax Labs' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our GOVX earnings forecast.

How were GeoVax Labs' earnings last quarter?: GeoVax Labs, Inc. (NASDAQ:GOVX) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.06.
What is GeoVax Labs' stock symbol?: GeoVax Labs trades on the NASDAQ under the ticker symbol "GOVX."
How do I buy shares of GeoVax Labs?: Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GeoVax Labs' stock price today?: One share of GOVX stock can currently be purchased for approximately $0.55.
How much money does GeoVax Labs make?: GeoVax Labs (NASDAQ:GOVX) has a market capitalization of $14.65 million and generates $80,000.00 in revenue each year. The company earns $-14,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.
How can I contact GeoVax Labs?: GeoVax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The official website for the company is www.geovax.com. The company can be reached via phone at (678) 384-7220, via email at investor@geovax.com, or via fax at 678-384-7281.

This page (NASDAQ:GOVX) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial